OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

VIATRIS INC. O.N./  US92556V1061  /

Xetra
6/10/2024  10:03:08 AM Chg. -0.060 Volume Bid1:44:28 PM Ask1:51:41 PM Market Capitalization Dividend Y. P/E Ratio
9.640EUR -0.62% 3,101
Turnover: 29,819.326		 9.678Bid Size: 590 9.784Ask Size: 138 11.54 bill.EUR - -
GlobeNewswire 6/3 Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
GlobeNewswire 5/10 Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire 5/6 Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
GlobeNewswire 5/3 Ocuphire Pharma to Present at the Aegis Virtual Conference
GlobeNewswire 5/1 NeurologyLive® and CMSC Announce the 3rd Annual Class of Inductees
GlobeNewswire 4/22 Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
GlobeNewswire 4/11 First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...
GlobeNewswire 4/1 Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...
GlobeNewswire 3/20 Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Boar...
GlobeNewswire 3/8 Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...
TeleTrader 2/28 US closes lower after GDP data, ahead of earnings
GlobeNewswire 2/28 Idorsia and Viatris enter into a significant global research and development collaboration
GlobeNewswire 2/23 Ocuphire Pharma to Present in the BIO CEO & Investor Conference
GlobeNewswire 2/15 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 2/14 ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis R...
GlobeNewswire 2/14 Ocuphire Pharma Strengthens Leadership Team with Key Appointments
GlobeNewswire 2/5 Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...
GlobeNewswire 2/2 Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire 1/24 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 1/4 Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...
GlobeNewswire 1/2 VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stoc...
GlobeNewswire 11/30/2023 Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
GlobeNewswire 11/30/2023 Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries ...
GlobeNewswire 11/27/2023 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 11/27/2023 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer